Relypsa (Relypsa) Change In Receivables : $-1.40 Mil (TTM As of Jun. 2016)

View and export this data going back to 2013. Start your Free Trial

What is Relypsa Change In Receivables?

Relypsa's change in receivables for the quarter that ended in Jun. 2016 was $-0.97 Mil. It means Relypsa's Accounts Receivable increased by $0.97 Mil from Mar. 2016 to Jun. 2016 .

Relypsa's change in receivables for the fiscal year that ended in Dec. 2015 was $-0.88 Mil. It means Relypsa's Accounts Receivable increased by $0.88 Mil from Dec. 2014 to Dec. 2015 .

Relypsa's Accounts Receivable for the quarter that ended in Jun. 2016 was $1.34 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Relypsa's Days Sales Outstanding for the three months ended in Jun. 2016 was 23.38.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Relypsa's liquidation value for the three months ended in Jun. 2016 was $64.01 Mil.

Relypsa Change In Receivables Historical Data

The historical data trend for Relypsa's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relypsa Change In Receivables Chart

Relypsa Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Change In Receivables

-2.98

2.74

-0.18

-0.88

Relypsa Quarterly Data
	Dec11	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
Change In Receivables	Get a 7-Day Free Trial												0.40	-0.22	-0.19	-0.02	-0.97

Relypsa Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.40 Mil.

Relypsa (NAS:RLYP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Relypsa's Days Sales Outstanding for the quarter that ended in Jun. 2016 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.338	/	5.221	*	91
=	23.38

2. In Ben Graham's calculation of liquidation value, Relypsa's accounts receivable are only considered to be worth 75% of book value:

Relypsa's liquidation value for the quarter that ended in Jun. 2016 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	257.726	-	210.657	+	0.75 * 1.338	+	0.5 * 31.881
=	64.01

Relypsa Change In Receivables Related Terms

Thank you for viewing the detailed overview of Relypsa's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Relypsa (Relypsa) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relypsa Inc (NAS:RLYP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.relypsa.com

Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.

Executives

Ronald A. Krasnow	officer: See Remarks	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kristine M Ball	officer: Chief Financial Officer & SVP	C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mcgirr David W J	director	33 PHEASANT LANE, GREENWICH CT 06830
Paul J Hastings	director	61 HARTFORD STREET, SAN FRANCISCO CA 94114
John A Orwin	director, officer: President & CEO	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Wilhelm Stahl	officer: SVP, Chief Technology Officer	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
J. Scott Garland	officer: SVP & Chief Commercial Officer	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
John P. Butler	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Helen Torley	director	C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James D Dondero	10 percent owner	300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Relypsa (Relypsa) Headlines

From GuruFocus

Insiders Buy Stock in Wynn Resorts, Bank of New York Mellon

By Tiziano Frateschi Tiziano Frateschi • 10-26-2015